Clinical trial · Observational
Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
Long-Term Follow-up Protocol for Subjects Treated With a CAR T-Cell Product on a Juno-Sponsored Clinical Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Eligible subjects will be enrolled in Celgene's long-term follow-up protocol for subjects previously treated with a CAR T-cell product.
Summary
Brief summary (as posted)
This study will provide long-term follow-up for patients who have received treatment with a Juno CAR T-cell product in a Juno-sponsored clinical trial. In this study, patients will be followed for up to 15 years after their last dose of Juno CAR T cells for evaluation of delayed adverse events, presence of persisting CAR T-cell vector sequences, presence of replication-competent retrovirus (RCR) or lentivirus (RCL), and survival.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | ONTOLOGY_EXACT | 0.98 |
| Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma | CURATED_BROADER | 0.80 |
| Follicular Lymphoma | Follicular Lymphoma | ONTOLOGY_EXACT | 0.98 |
| Mantle Cell Lymphoma | Mantle Cell Lymphoma | ONTOLOGY_EXACT | 0.98 |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Non Hodgkin Lymphoma | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| JCAR017 | Genetic | — | UNRESOLVED |
| JCARH125 | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- JCAR017-treated
- description
- Patients who received previous treatment with JCAR017
- interventionNames
- Genetic: JCAR017
- label
- JCARH125-treated
- description
- Patients who received previous treatment with JCARH125
- interventionNames
- Genetic: JCARH125
Primary outcomes (3)
- measure
- Proportion of patients with adverse events
- timeFrame
- 15 years from last treatment
- measure
- Proportion of patients with detectable viral vector sequences
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients who have received at least one dose of a Juno CAR T-cell product (listed above) in a Juno-sponsored clinical trial * Patients who have provided informed consent for the long-term follow-up study Exclusion Criteria: * None. All patients who have previously received treatment with a Juno CAR T-cell product are eligible for this long-term follow-up study.
References
Publications (0)
Data not yet available